Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 7:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 13,756 matching trials from the live ClinicalTrials.gov search.
Conditions
HIV Infections, Pneumococcal Infections
Interventions
Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
31
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 21 more
Terminated No phase listed Observational

RapidTEG MA Validation

NCT01428102
Conditions
Coagulation, Platelet Function
Interventions
Not listed
Lead sponsor
Haemonetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Baltimore, Maryland • Knoxville, Tennessee
Conditions
Cancer
Interventions
BMS-986242, Nivolumab
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland
Conditions
Scleroderma, Connective Tissue Diseases
Interventions
Oral bovine type I collagen, Placebo
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Farmington, Connecticut + 9 more
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
Interventions
NHS7108, Zenpep®
Drug
Lead sponsor
Aimmune Nestlé Health Science US R&D, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Conditions
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Echocardiography Test
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
192
States / cities
Jonesboro, Arkansas • Beverly Hills, California • Los Angeles, California + 163 more
Conditions
Adult Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
Interventions
Asparaginase, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Downey, California + 36 more
Withdrawn No phase listed Observational Accepts healthy volunteers

Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics

NCT01246128
Conditions
Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Catonsville, Maryland
Conditions
Advanced Breast Cancer
Interventions
HKI-272, trastuzumab
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
6
States / cities
Duarte, California • Los Angeles, California • Pasadena, California + 3 more
Conditions
Tracheal Stenosis
Interventions
Bronchoscopy, carbon dioxide (CO2) laser wedge resection, Radial incision with dilation
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
19 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Iowa City, Iowa • Kansas City, Kansas • New Orleans, Louisiana + 11 more
Conditions
Vitamin A Deficiency, Maternal Mortality, Infant Mortality
Interventions
Vitamin A or Beta-Carotene Supplements
Dietary Supplement
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
15 Years to 49 Years · Female only
Enrollment
59,666 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy

NCT00285337
Conditions
Cervical Spondylotic Myelopathy
Interventions
Laminectomy and Laminoplasty
Procedure
Lead sponsor
AOSpine North America Research Network
Network
Eligibility
Not listed
Enrollment
321 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
12
States / cities
Thornton, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 8 more
Conditions
Transitional Cell Cancer of Renal Pelvis and Ureter
Interventions
padeliporfin VTP
Drug
Lead sponsor
Steba Biotech S.A.
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Irvine, California • Los Angeles, California • Atlanta, Georgia + 9 more
Terminated Phase 3 Interventional Results available

PROMINENT-Eye Ancillary Study (Protocol AD)

NCT03345901
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Pemafibrate, Placebo
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
69
States / cities
Phoenix, Arizona • Campbell, California • Glendale, California + 52 more
Conditions
Essential Tremor
Interventions
Exablate Model 4000 Type 1.0/1.1
Device
Lead sponsor
InSightec
Industry
Eligibility
22 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Stanford, California • Baltimore, Maryland • New York, New York + 4 more
Conditions
HIV Infections, Pregnancy
Interventions
Lamivudine, Lamivudine/Zidovudine, Nelfinavir mesylate, Nevirapine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years and older · Female only
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
44
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 28 more
Conditions
HIV Infection
Interventions
Abacavir/Lamivudine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
178
States / cities
Montgomery, Alabama • Glendale, Arizona • Phoenix, Arizona + 123 more
Conditions
Partial Epilepsies, Partial Onset Seizures
Interventions
lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Baltimore, Maryland • Chesterfield, Missouri + 4 more
Conditions
Hypogonadotropic Hypogonadism
Interventions
BGS649, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 45 more
Conditions
Achondroplasia
Interventions
Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg, Infigratinib 0.128 mg/kg, Infigratinib 0.25 mg/kg
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Oakland, California • Wilmington, Delaware • Baltimore, Maryland + 2 more
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging of the Brain with and without Contrast, Monalizumab, Oleclumab, Radiation Therapy
Radiation · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
56
States / cities
Atlanta, Georgia • Augusta, Georgia • Boise, Idaho + 42 more
Conditions
Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Lung Cancer
Interventions
Imetelstat Sodium (GRN163L)
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Baltimore, Maryland • Dallas, Texas • Houston, Texas + 1 more